Drug factory · FDA FEI 3002807772
Novartis Pharma AG
Lichtstrasse 35, Basel, Switzerland
Problems found, fixed voluntarily at FDA's last inspection, Dec 18, 2025.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
10 drug inspections on record since 2008: 4 with no problems, 6 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Deferoxamine | Tests it | Mitem Pharma | 87081-467 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Dec 18, 2025 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Aug 30, 2022 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jul 12, 2019 | No problems found | Drug Quality Assurance | — |
| Jul 6, 2017 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jan 14, 2015 | No problems found | Drug Quality Assurance | — |
| Dec 5, 2013 | No problems found | Drug Quality Assurance | — |
| Jul 26, 2012 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Jul 18, 2012 | No problems found | Drug Quality Assurance | — |
| Nov 21, 2008 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Nov 6, 2008 | Problems found, fixed voluntarily | Bioresearch Monitoring | — |
Registered with FDA for: analysis; api manufacture; manufacture.